Because the action never stops.

October 2019

New Study Confirms TwitchView® Quantitative Monitor for Neuromuscular Blockade is Comparable to Gold Standard Mechanomyography

Seattle, WA, October 18, 2019 --( Blink Device Company announced today that a study comparing the TwitchView® quantitative train-of-four (TOF) electromyography-based monitor to accelerometry and mechanomyography has been published in the journal Anaesthesia ( The results demonstrate that the TwitchView monitor closely resembles mechanomyography, often considered to be the laboratory gold standard, while accelerometry frequently produces train-of-four ratio values > 1.0, complicating the interpretation of acceleromyography results in the clinical setting. 


Read More

October 2019

Electromyographic TOF Twitch Monitors Shown Closest to Manual Palpation

Montreal—Although peripheral nerve stimulation is commonly used to assess neuromuscular transmission when dosing neuromuscular blocking agents and reversal drugs, quantitative twitch monitors have been shown to be more accurate than palpation for measuring the train-of-four (TOF) ratio.

But which type of monitor—mechanomyography, acceleromyography or electromyography—is most accurate?

New research has concluded that the three techniques have substantial agreement, but electromyography most closely emulates manual palpation and acceleromyography frequently underestimates twitch counts.


Read More

June 2019

Blink Device Company Announces TwitchView™ Quantitative Monitor for Neuromuscular Blockade is Now Compatible with Major Electronic Medical Records

Seattle, WA, June 04, 2019 --( Blink Device Company announced today that the TwitchView™ quantitative train-of-four (TOF) monitor now integrates with most major electronic medical records (EMR). Commercially available in the United States, Europe, and South Korea, the TwitchView™ neuromuscular TOF monitor uses electromyography (EMG) to provide clinicians with reliable and accurate quantitative TOF data. 


Read More

October 2018

Blink Device Company Launches TwitchView™ Neuromuscular TOF Monitor at American Society of Anesthesiologists Annual Meeting

Seattle, WA, October 10, 2018 --( Blink Device Company announced today that it is formally launching TwitchView™, a new quantitative train-of-four monitor for neuromuscular blockade, at the American Society of Anesthesiologists annual conference in San Francisco.


Read More

September 2018

Medical Device Manufacturer Blink Device Company Signs Distribution Agreement with KCPMED

Seattle, WA, September 05, 2018 --( Blink Device Company announced today that it has partnered with KCPMED to introduce TwitchView, a new quantitative train-of-four monitor for neuromuscular blockade, to the Korean market.

Read More

June 2018

Blink’s TwitchView Neuromuscular Blockade Monitor Cleared in Europe

Blink Device Company, out of Seattle, Washington, landed the CE Mark in Europe, allowing it to introduce its TwitchView neuromuscular blockade monitor. The system quantifies the depth of a neuromuscular blockade under anesthesia using electromyography (EMG). 


Read More

April 2018

Blink’s TwitchView for Neuromuscular Blockade Monitoring

Blink Device Company, a firm based in Seattle, Washington, won FDA clearance for and is releasing in the United States its TwitchView monitor. The device is used for monitoring the depth of neuromuscular blockade under anesthesia, and the company claims it is the first standalone electromyography (EMG) monitor available in the U.S. The company is working on obtaining clearance in Europe.


Read More

March 2018

Blink Receives FDA 510(k) Clearance for TwitchView

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).


Read More

Logo Border.png

©2019 by